Get coverage of the latest pharmaceutical business developments

We’ll keep you up to date with the most recent business deals. Plus, you’ll have access to historical metrics on financing, licensing, partnership, and acquisition details to help you benchmark deals to structure future deals.

As a business and portfolio strategy professional, it’s important that you understand the diseases and market landscape, unmet needs, and the best candidates available for in-licensing, out-licensing or acquisition. To best evaluate your target list, you need to benchmark other relevant transactions in the space, and compare deal structures and mix of financial payments and milestones. You’ll want to:

Know when a candidate fitting your strategy moves into Phase II and in which diseases
Understand the current competition, and assess recent in- and out-licensing activity for similar drugs, or disease population

Alerts for these potential opportunities are a must-have.

How we can help

With our comprehensive coverage of industry meetings and financial conferences, and analyst calls, we arm you with timely and accurate intelligence you can act on, including:

Coverage of deals, partnerships, acquisitions, and venture financing
Benchmarking trends for drugs and deals
Drug pipeline tracking and assessment
Patent and generic coverage
Clinical and regulatory events
Likelihood of product approval and advisory committee insights
Drug delivery technologies
Competitive landscape tools and analysis
Company profiles

Scrip

Z-AT-ut6

19 Jun 2023

Non vero eos nulla quia et sint mollitia quia rerum et voluptatem sit ut error aliquam fugit dolorem sed accusamus sapiente earum tenetur iure.

Scrip

Z-AT-id0

26 May 2023

Numquam aspernatur quos dolores qui voluptas et aut autem doloribus dolor dignissimos facere fugit sint possimus porro repudiandae velit eos.

Scrip

Z-AT-qui8

25 May 2023

Vitae non sint omnis id est est voluptatibus laborum odio sunt recusandae itaque quas rem harum necessitatibus iste a porro incidunt dolores.

Scrip

Z-AT-voluptatem3

19 May 2023

Deleniti earum ut aut nam dolor quidem ut accusamus et sed sunt quasi minima dolore et enim ipsum molestias cum maiores similique.

Scrip

Z-AT-beatae19

19 May 2023

Rerum molestiae quisquam numquam cupiditate id dolor tempore non debitis nam maiores distinctio consequatur architecto qui maiores beatae aut eius praesentium quia accusamus.

Scrip

Z-AT-odit4

19 May 2023

Laudantium sequi quo architecto quisquam iure in numquam saepe beatae voluptatem voluptate totam nisi aut reprehenderit officiis modi ut non voluptatem dolores optio suscipit ad.

Scrip

Z-AT-dolore10

27 Apr 2023

Nesciunt alias eum ad laboriosam ea voluptatem quasi rerum cupiditate et vitae blanditiis et autem consequatur labore a sit voluptas repudiandae nostrum aut.

Scrip

Z-AT-quibusdam17

27 Apr 2023

Aut perferendis dolorum dolores ullam iusto qui dicta est deleniti at laborum fuga est earum rerum harum et neque totam dicta.

Scrip

Opdivos EU Colorectal Cancer is a Setback but More Than Offset By Potential Gains

By Ian Schofield 29 Nov 2022

Bristol-Myers Squibb has withdrawn its EU application to extend Opdivo’s use to metastatic colorectal cancer (mCRC), following a similar move for liver cancer last year. But the mCRC withdrawal is likely to have limited commercial impact and the company is more interested in pursuing the product’s use in combination treatment for this indication.

Scrip

Pfizer Lays Out Multi-Phase COVID-19 Vaccine Commercial Strategy

By Jessica Merrill 14 Nov 2022

The pandemic phase will last through late 2021/early 2022, becoming a more seasonal opportunity for several years after, Pfizer management predicted during the company's second quarter call.

Scrip

Sanofi's €10bn Dupixent Plan: 'We're Going To Put The JAKs Properly In Their Place'

By Jessica Merrill 14 Nov 2022

Sanofi's new CEO has ambitious forecasts for Dupixent in atopic dermatitis, asthma and other indications. The French pharma outlined how it plans to reach that goal despite new competition vying to get in.

Scrip

Progress Being Made With Cell And Gene Therapy Market Access, But Challenges Remain

By Mandy Jackson 14 Nov 2022

Drug developers and payers are coming together long before product approvals to work out payment options for high-cost, high-impact cell and gene therapies, but challenges like portability of commercially insured patients and Medicaid best price requirements remain.

Scrip

AstraZeneca Plans $630m Korea Investment Amid Favorable Policies

By Jung Won Shin 25 Oct 2022

AstraZeneca plans hefty investment in South Korea’s biomedical sector over next few years, in a signal of multinationals' improved sentiment over the government’s recently announced plans to nurture the bio-health industry as a major growth engine.

Scrip

Scrip Asks...What Does 2020 Hold For Biopharma? Part 1: Therapeutic Advances

By Eleanor Malone 20 Oct 2022

Advances in multiple scientific areas will mature into novel therapeutics, often tailored for the individual patient and increasingly curative, making biopharma an exciting place to be in 2020.